IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society

The 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences, and the 2012 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 3–6, 2012 in San Diego, CA. The meeting drew over 800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a prelude to the main events, a pre-conference workshop held on December 2, 2012 focused on intellectual property issues that impact antibody engineering. The Antibody Engineering Conference was composed of six sessions held December 3–5, 2012: (1) From Receptor Biology to Therapy; (2) Antibodies in a Complex Environment; (3) Antibody Targeted CNS Therapy: Beyond the Blood Brain Barrier; (4) Deep Sequencing in B Cell Biology and Antibody Libraries; (5) Systems Medicine in the Development of Antibody Therapies/Systematic Validation of Novel Antibody Targets; and (6) Antibody Activity and Animal Models. The Antibody Therapeutics conference comprised four sessions held December 4–5, 2012: (1) Clinical and Preclinical Updates of Antibody-Drug Conjugates; (2) Multifunctional Antibodies and Antibody Combinations: Clinical Focus; (3) Development Status of Immunomodulatory Therapeutic Antibodies; and (4) Modulating the Half-Life of Antibody Therapeutics. The Antibody Society’s special session on applications for recording and sharing data based on GIATE was held on December 5, 2012, and the conferences concluded with two combined sessions on December 5–6, 2012: (1) Development Status of Early Stage Therapeutic Antibodies; and (2) Immunomodulatory Antibodies for Cancer Therapy.

[1]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[2]  C. Mackay,et al.  Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. , 1996, Gastroenterology.

[3]  J. Marks,et al.  Toward selection of internalizing antibodies from phage libraries. , 1999, Biochemical and biophysical research communications.

[4]  H. Katinger,et al.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.

[5]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[6]  Philip R. Johnson,et al.  Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer , 2002, Journal of Virology.

[7]  A. Casadevall,et al.  Isotype Can Affect the Fine Specificity of an Antibody for a Polysaccharide Antigen1 , 2002, The Journal of Immunology.

[8]  J. Tanha,et al.  Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endothelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[10]  G. Schuurhuis,et al.  C-Type Lectin-Like Molecule-1 , 2004, Cancer Research.

[11]  K Dane Wittrup,et al.  Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* , 2004, Journal of Biological Chemistry.

[12]  Christoph E. Dumelin,et al.  Encoded self-assembling chemical libraries , 2004, Nature Biotechnology.

[13]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[14]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[15]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[16]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[17]  A. Casadevall,et al.  Variable-Region-Identical Antibodies Differing in Isotype Demonstrate Differences in Fine Specificity and Idiotype1 , 2005, The Journal of Immunology.

[18]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[19]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[20]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[21]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[22]  F. Bootz,et al.  Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis , 2007, Arthritis research & therapy.

[23]  A. Villa,et al.  The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. , 2007, Cancer research.

[24]  A. Casadevall,et al.  The Immunoglobulin Heavy Chain Constant Region Affects Kinetic and Thermodynamic Parameters of Antibody Variable Region Interactions with Antigen* , 2007, Journal of Biological Chemistry.

[25]  M. Glennie,et al.  Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. , 2007, Blood.

[26]  Chien-Hsing Chang,et al.  The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity , 2007, Clinical Cancer Research.

[27]  M. Glennie,et al.  Eradication of lymphoma by CD 8 T cells following anti-CD 40 monoclonal antibody therapy is critically dependent on CD 27 costimulation , 2007 .

[28]  Lennart Martens,et al.  The minimum information about a proteomics experiment (MIAPE) , 2007, Nature Biotechnology.

[29]  Christian Lovis,et al.  Automatic medical encoding with SNOMED categories , 2008, BMC Medical Informatics Decis. Mak..

[30]  A. Cohen,et al.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  Sandra Lynch,et al.  An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. , 2008, Journal of molecular biology.

[32]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[33]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[34]  B Tolner,et al.  Data standards for minimum information collection for antibody therapy experiments. , 2009, Protein engineering, design & selection : PEDS.

[35]  Sandra Lynch,et al.  Developing intrabodies for the therapeutic suppression of neurodegenerative pathology , 2009, Expert opinion on biological therapy.

[36]  Jan Berka,et al.  Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.

[37]  Bryn Nelson.  Data sharing: Empty archives , 2009, Nature.

[38]  F. Bootz,et al.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis , 2009, Arthritis research & therapy.

[39]  R. Egan,et al.  The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.

[40]  P. Kufer,et al.  Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. , 2009, Leukemia research.

[41]  András Fiser,et al.  Identification of Linear Epitopes in Bacillus anthracis Protective Antigen Bound by Neutralizing Antibodies* , 2009, The Journal of Biological Chemistry.

[42]  A. Lugovskoy,et al.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR , 2009 .

[43]  A. Korman,et al.  Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors , 2009, Clinical Cancer Research.

[44]  Rajeeva Singh,et al.  Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. , 2010, Bioconjugate chemistry.

[45]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[46]  T. Logtenberg,et al.  Generation of stable cell clones expressing mixtures of human antibodies , 2010, Biotechnology and bioengineering.

[47]  Anna M Wu,et al.  Antibody vectors for imaging. , 2010, Seminars in nuclear medicine.

[48]  P. Moore,et al.  Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.

[49]  P. Moore,et al.  Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. , 2010, Arthritis and rheumatism.

[50]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[51]  C. Pyke,et al.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.

[52]  A. Wu,et al.  ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). , 2010, Protein engineering, design & selection : PEDS.

[53]  B. Liu,et al.  Amyloid-β Immunotherapy for Alzheimers Disease , 2010 .

[54]  Christoph E. Dumelin,et al.  Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library. , 2010, Bioconjugate chemistry.

[55]  Kunihiro Hattori,et al.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization , 2010, Nature Biotechnology.

[56]  H. Yagita,et al.  Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. , 2010, Biochemical and biophysical research communications.

[57]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Baselga,et al.  CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. , 2010, Clinical breast cancer.

[59]  Q. Zeng,et al.  Targeting Intracellular Oncoproteins with Antibody Therapy or Vaccination , 2011, Science Translational Medicine.

[60]  Qing-hui Zhou,et al.  Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. , 2011, Molecular pharmaceutics.

[61]  D. Cox,et al.  Synthetic antibodies designed on natural sequence landscapes. , 2011, Journal of molecular biology.

[62]  Martin C. Wright,et al.  A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor , 2011, mAbs.

[63]  G. Adams,et al.  Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.

[64]  J. Bading,et al.  Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging. , 2011, Bioconjugate chemistry.

[65]  Qing-hui Zhou,et al.  Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. , 2011, Molecular pharmaceutics.

[66]  Henrik Næsted,et al.  Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use , 2011, Biotechnology and bioengineering.

[67]  I. Brukner,et al.  Host and pathogen factors for Clostridium difficile infection and colonization. , 2011, The New England journal of medicine.

[68]  P. Kaufmann,et al.  Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies. , 2011, Atherosclerosis.

[69]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[70]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[71]  C. Klein,et al.  Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 , 2011, Molecular Cancer Therapeutics.

[72]  D. Butler,et al.  Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments , 2011, PloS one.

[73]  W. Ouwehand,et al.  Cross-domain inhibition of TACE ectodomain , 2011, Proceedings of the National Academy of Sciences.

[74]  M. Cragg,et al.  Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.

[75]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[77]  Stephen L. Hauser,et al.  Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation , 2011, Proceedings of the National Academy of Sciences.

[78]  J. Stockman.  Treatment with Monoclonal Antibodies against Clostridium difficile Toxins , 2011 .

[79]  G. Henze,et al.  Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia , 2011, Leukemia.

[80]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[81]  P. S. Andersen,et al.  Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. , 2012, Blood.

[82]  D. Burton,et al.  Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2 , 2012, PloS one.

[83]  A. Casadevall,et al.  Variable Region Identical Immunoglobulins Differing in Isotype Express Different Paratopes* , 2012, The Journal of Biological Chemistry.

[84]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[85]  M. Nussenzweig,et al.  A mouse model for HIV-1 entry , 2012, Proceedings of the National Academy of Sciences.

[86]  J. Byrd,et al.  Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. , 2012, Blood.

[87]  Sean A Beausoleil,et al.  Proteomics-directed cloning of circulating antiviral human monoclonal antibodies , 2012, Nature Biotechnology.

[88]  D. Butler,et al.  Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies , 2012, mAbs.

[89]  W. Pardridge,et al.  Brain Protection from Stroke with Intravenous TNFα Decoy Receptor-Trojan Horse Fusion Protein , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[90]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[91]  S. Ansell,et al.  Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia , 2012, Clinical Cancer Research.

[92]  B. Kennedy,et al.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. , 2012, The Journal of infectious diseases.

[93]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[94]  K. Burke,et al.  Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates , 2012, Inflammatory bowel diseases.

[95]  James J. Campbell,et al.  Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells , 2012, Molecular Cancer Therapeutics.

[96]  F. White,et al.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. , 2011, Protein engineering, design & selection : PEDS.

[97]  Michael A. Stravs,et al.  Discovery of small-molecule interleukin-2 inhibitors from a DNA-encoded chemical library. , 2012, Chemistry.

[98]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[99]  Sean A Beausoleil,et al.  A proteomics approach for the identification and cloning of monoclonal antibodies from serum , 2012, Nature Biotechnology.

[100]  Q. Zeng,et al.  Awaiting a new era of cancer immunotherapy. , 2012, Cancer research.

[101]  W. Pardridge,et al.  Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. , 2012, Methods in enzymology.

[102]  B. Liu,et al.  Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study , 2012, Neurodegenerative Diseases.

[103]  E. Brunette,et al.  Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. , 2013, Molecular pharmaceutics.